The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and AI.
On the last day of 2024, Lexington’s Valo Health Inc. also shared that its Phase 2 trial of OPL-0401 in patients with diabetic retinopathy did not meet its primary or secondary end ...
Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.
The companies originally partnered in September 2023 in an agreement that allowed for the development of up to 11 drug programmes, primarily focused on cardiovascular disease, through which Valo ...
Zacks.com on MSN16d
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to BuyNVO Expands Collaboration Agreement With Valo Health In the last press release, Novo Nordisk announced expanding its partnership with Valo, leveraging the latter’s extensive human dataset and ...
Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...
Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...
The companies originally partnered in September 2023 in an agreement that allowed for the development of up to 11 drug programmes, primarily focused on cardiovascular disease, through which Valo was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback